A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

NCT01059630 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

413

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Bendamustine

Sponsor

Genentech, Inc.

Collaborators

[object Object]